CytoMed Therapeutics to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced it will be presenting at The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference to be...
ICWS Successfully Concludes 2nd Global Program on Cutting-edge Chest Wall Surgery Techniques
GUANGZHOU, China, July 21, 2025 /PRNewswire/ -- The 2nd "Latest Chest Wall Surgery Technique Global Training Program", hosted by the Institute of Chest Wall Surgery (ICWS) of Guangdong Second Provincial General Hospital, was successfully held from July 16 to 18, 2025. The program brought together 10 thoracic surgeons from the United States, Romania, India, Armenia, Pakistan, Malaysia, Mexico, and...
Fapon Shines at JITMM 2023
DONGGUAN, China, Dec. 20, 2023 /PRNewswire/ -- Fapon, a global leading life sciences company, showcased its expertise at the Joint International Tropical Medicine Meeting (JITMM) 2023, the leading tropical-medicine conference in Southeast Asia held in Bangkok, Thailand, from December 12th to 15th. Committed to fostering local collaboration and empowering local IVD industry in...
NABR Comment on IUCN Determination
WASHINGTON, Oct. 14, 2025 /PRNewswire/ -- The International Union for Conservation of Nature (IUCN) issued a decision on October 9, 2025, to retain the "Endangered" status determination for long-tailed macaque ("LTM") monkeys (Macaca fascicularis). The latest issuance by the IUCN follows a 2023 petition filed by the National Association for Biomedical Research (NABR) challenging the...
First Proton Therapy Treatment Delivered in Southeast Asia at Her Royal Highness Princess Maha Chakri Sirindhorn Proton Center, Thailand
BANGKOK, Feb. 9, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company, today announced that Her Royal Highness Princess Maha Chakri Sirindhorn Proton Center has begun treating patients with its new Varian ProBeam® proton therapy system, the first of its kind in Thailand and Southeast Asia. Clinicians used the new system to target a complicated abdominal cancer using carefully shaped high-definition...
LEADERS IN NUTRITIONAL MEDICINE ON CUSP OF BREAKTHROUGH GUIDELINES TO TACKLE LONG-COVID SYMPTOMS
Guidelines for health practitioner diagnosis of Long-COVID are in review Understanding of mitochondrial health integral to post-pandemic recovery, say experts Ninety per cent of people hospitalised with COVID-19 have significant underlying medical conditions, and are more likely to develop Long COVID SYDNEY, Sept. 5, 2022 /PRNewswire/ -- Australia's leaders in Integrative Medicine are closer to developing guidelines for diagnosis...
MGI Tech Introduces DNBSEQ-T7+: A Next-Generation ‘Data Mining Machine’ for Genomics
SHENZHEN, China, Sept. 15, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, announced the launch of the DNBSEQ-T7+, its latest high-throughput sequencer. Designed to meet the rising demand for large-scale genomic research, the T7+ delivers more than 14 Tb/day of...
Mintal Tracker Wins 2023 iF DESIGN AWARD
The award-winning app was recognized as Solution for Sleep Disorders SUNNYVALE, Calif., May 30, 2023 /PRNewswire/ -- Mintal Tracker, a sleep tracking app driven by artificial intelligence (AI) technology that offers a scientific approach to healthier sleep, was named as a winner of this year's iF DESIGN AWARD. Mintal Tracker won in the Solution for Sleep Disorders discipline...
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
SHANGHAI, March 30, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) reported positive topline results from a second Phase 3 study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of moderately to severely active ulcerative colitis (UC). In this 52-week study,...
HistoSonics Announces First Ever Kidney Tumor Treatment Using Histotripsy
Leeds Teaching Hospitals NHS Trust, (UK) Performs Non-Invasive Histotripsy in Patient with Primary Solid Renal Tumor MINNEAPOLIS, March 30, 2023 /PRNewswire/ -- HistoSonics, (www.histosonics.com), the developer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the first kidney patient has been treated using the Company's histotripsy platform. The procedure was performed in Leeds, UK,...
